Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reuma.2012.03.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-Induced Osteomalacia Localized by Systemic Venous Sampling and Ga-DOTATOC Positron Emission Tomography.
JCEM Case Rep
February 2025
First Department of Internal Medicine, Wakayama Medical University, Wakayama City, Wakayama 641-8509, Japan.
Tumor-induced osteomalacia is characterized by hypophosphatemia and fragility fractures caused by fibroblast growth factor 23 (FGF23)-producing tumors. We report a case of tumor-induced osteomalacia in which the tumor location could be determined by gallium 68 (Ga)-DOTATOC positron emission tomography (PET)/computed tomography (CT). A 74-year-old woman had recurrent fractures and bone pain.
View Article and Find Full Text PDFPhosphaturic mesenchymal tumor demonstrated by Ga-DOTATATE PET/CT in a patient: a case report.
EJNMMI Rep
September 2024
Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome caused by abnormally high levels of fibroblast growth factor 23 (FGF-23), most commonly produced and secreted by small phosphaturic mesenchymal tumors (PMT). These tumors can show various anatomic locations throughout soft tissue and bone. The presence of the tumor itself rarely causes symptoms.
View Article and Find Full Text PDFAn image of a FGF-23-producing tumor resulting in osteomalacia.
J Bras Nefrol
June 2024
Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Clínica Médica, Divisão de Nefrologia, Campinas, SP, Brazil.
Successful Superficial Blood Sampling to Localize a Fibroblast Growth Factor-23-Producing Tumor.
Am J Case Rep
April 2024
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
BACKGROUND Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome caused by aberrant fibroblast growth factor-23 (FGF-23)-producing tumors. Early surgical resection is the optimal strategy for preventing TIO progression. Thus, tumor localization is a priority for successful treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!